Drug intelligence

Experimental drug profiles

Independent profiles of experimental medical drugs. Each one combines live clinical trial records and FDA status with our sourced analysis of the evidence: what the drug does, what the trials have shown, and what could change its prospects.

Not yet approved

CagriSema

Novo Nordisk · Peptide combination (once-weekly injection) · Metabolic

Submitted to the FDA in December 2025 for weight management; decision expected in late 2026 (company-reported)

33 registered trials (20 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

FDA-approved

Daraxonrasib (Rasonque)

Revolution Medicines · Small molecule (oral, once daily) · Oncology

FDA-approved August 26, 2026 for previously treated metastatic pancreatic cancer after roughly doubling survival in Phase 3

22 registered trials (5 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

FDA-approved

Enlicitide (Lipfendra)

Merck & Co. (MSD) · Oral PCSK9 inhibitor (once-daily tablet) · Cardiovascular

FDA-approved July 2026 as the first oral PCSK9 inhibitor; cardiovascular outcomes trial ongoing

34 registered trials (8 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Major setback

Ivonescimab

Summit Therapeutics · Bispecific antibody · Oncology

FDA issued a Complete Response Letter on November 15, 2026: progression-free survival improved, but overall survival was not statistically significant

192 registered trials (18 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Not yet approved

Lepodisiran

Eli Lilly and Company · Small interfering RNA (siRNA) · Cardiovascular

Phase 3 outcomes trial (ACCLAIM-Lp(a)) underway; a single dose lowered Lp(a) by about 94% in Phase 2

8 registered trials (2 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Not yet approved

Muvalaplin

Eli Lilly and Company · Small molecule (oral, once daily) · Cardiovascular

First oral Lp(a)-lowering drug in a Phase 3 outcomes trial (MOVE-Lp(a)), now recruiting

6 registered trials (1 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Approved outside the U.S.

Obicetrapib (Ubeslo)

NewAmsterdam Pharma · Small molecule (oral, once daily) · Cardiovascular

Approved in the EU in 2026 for high cholesterol; no FDA approval; 9,541-patient outcomes trial ongoing

29 registered trials (7 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Not yet approved

Olpasiran

Amgen · Small interfering RNA (siRNA) · Cardiovascular

Phase 3 cardiovascular outcomes trial ongoing; Phase 2 showed near-complete Lp(a) lowering

10 registered trials (3 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

FDA-approved

Orforglipron (Foundayo)

Eli Lilly and Company · Small molecule (oral, once daily) · Metabolic

FDA-approved for chronic weight management (April 2026); type 2 diabetes submitted in the U.S.

53 registered trials (29 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Major setback

Pelacarsen

Novartis · Antisense oligonucleotide · Cardiovascular

Phase 3 outcomes trial missed its primary endpoint despite a 78% Lp(a) reduction

18 registered trials (8 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Not yet approved

Retatrutide

Eli Lilly and Company · Peptide (once-weekly injection) · Metabolic and cardiovascular

Phase 3 obesity program complete; Lilly plans to file with the FDA in Q1 2027

34 registered trials (14 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Approved outside the U.S.

Sacituzumab tirumotecan

Merck & Co. (MSD) · Antibody–drug conjugate (ADC) · Oncology

Approved in China since 2024; under FDA priority review for previously treated endometrial cancer, decision date June 15, 2027 (company-reported)

129 registered trials (28 Phase 3 or later) · Evidence reviewed through Nov 20, 2026

FDA-approved

Vepdegestrant (Veppanu)

Arvinas · PROTAC protein degrader (oral, once daily) · Oncology

FDA-approved May 1, 2026 for ESR1-mutated breast cancer: the first approved PROTAC

24 registered trials (2 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Not yet approved

Zanzalintinib

Exelixis · Small molecule (oral, once daily) · Oncology

FDA decision for metastatic colorectal cancer extended to March 3, 2027 after a major amendment (company-reported)

51 registered trials (8 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

Not yet approved

Zerlasiran

Silence Therapeutics · Small interfering RNA (siRNA) · Cardiovascular

Phase 2 complete; described by Silence as Phase 3-ready; Silence agreed to be acquired by Merck KGaA

2 registered trials (0 Phase 3 or later) · Evidence reviewed through Nov 19, 2026

What the status badges mean

FDA-approved
Approved by the FDA for at least one use. Other uses may still be in clinical trials.
Approved outside the U.S.
Approved by a regulator outside the United States, such as the European Commission, but not by the FDA.
Not yet approved
Not approved for any use. The drug is still being tested in clinical trials.
Major setback
A pivotal trial missed its main goal, or the FDA declined to approve the drug. Development may continue, and any approvals elsewhere are noted on the profile.

FDA status is checked against the FDA’s openFDA database. Each profile explains the decisions behind its badge, with sources.

How these profiles are built

  • Trial records are imported from ClinicalTrials.gov and re-checked on every update. Changes to status, dates, and endpoints are logged.
  • FDA status comes from the FDA’s openFDA database, not from company statements.
  • Analysis is written by Spectral Genomics Editorial. Every claim is sourced, and company-reported results are labeled.
  • Approval odds are shown only as labeled historical benchmarks. Read the methodology.